Online citations, reference lists, and bibliographies.
← Back to Search

Novel Strategies For Anterior Segment Ocular Drug Delivery.

K. Cholkar, Sulabh P. Patel, A. D. Vadlapudi, A. Mitra
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Research advancements in pharmaceutical sciences have led to the development of new strategies in drug delivery to anterior segment. Designing a new delivery system that can efficiently target the diseased anterior ocular tissue, generate high drug levels, and maintain prolonged and effective concentrations with no or minimal side effects is the major focus of current research. Drug delivery by traditional method of administration via topical dosing is impeded by ocular static and dynamic barriers. Various products have been introduced into the market that prolong drug retention in the precorneal pocket and to improve bioavailability. However, there is a need of a delivery system that can provide controlled release to treat chronic ocular diseases with a reduced dosing frequency without causing any visual disturbances. This review provides an overview of anterior ocular barriers along with strategies to overcome these ocular barriers and deliver therapeutic agents to the affected anterior ocular tissue with a special emphasis on nanotechnology-based drug delivery approaches.
This paper references
10.1001/ARCHOPHT.1983.01040020616024
Aqueous penetration of oral and topical indomethacin in humans.
D. Sanders (1983)
10.1016/B978-0-407-93272-2.50007-1
1 – General pharmacological principles
P. Davies (1981)
10.1089/jop.2010.0188
Ocular sustained release nanoparticles containing stereoisomeric dipeptide prodrugs of acyclovir.
J. Jwala (2011)
Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells
Laura Contreras-Ruiz (2011)
10.3109/03639041003680826
PLGA–PEG–PLGA hydrogel for ocular drug delivery of dexamethasone acetate
Y. Gao (2010)
10.4103/0975-1483.71623
Preparation and Evaluation of Nano-vesicles of Brimonidine Tartrate as an Ocular Drug Delivery System
P. Prabhu (2010)
10.1016/S0378-5173(00)00508-1
Ketorolac entrapped in polymeric micelles: preparation, characterisation and ocular anti-inflammatory studies.
A. Gupta (2000)
Improved corneal penetration of timolol by prodrugs as a means to reduce systemic drug load.
S. Chang (1987)
10.1167/IOVS.02-0907
Identification and functional characterization of a Na+-independent large neutral amino acid transporter, LAT1, in human and rabbit cornea.
Blisse Jain-Vakkalagadda (2003)
10.2174/1874764711205010083
Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis.
A. D. Vadlapudi (2012)
10.1021/CR941199Z
Hyaluronan: Preparation, Structure, Properties, and Applications.
Lubomír Lapcík L Jr and (1998)
10.1038/sj.gt.3301485
In vivo gene delivery into ocular tissues by eye drops of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) polymeric micelles
J. Liaw (2001)
10.1016/0039-6257(93)90036-7
Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy.
M. Abelson (1993)
10.1016/0039-6257(77)90087-X
Tear physiology and dry eyes.
F. Holly (1977)
Paracellular permeability of corneal and conjunctival epithelia.
A. Huang (1989)
10.1002/jps.22137
A nonionic surfactant/chitosan micelle system in an innovative eye drop formulation.
Ivan Pepić (2010)
10.1016/S0378-5173(01)00760-8
Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A.
A. M. de Campos (2001)
10.1167/IOVS.05-0495
Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance.
Amalia Enríquez de Salamanca (2006)
10.1089/jop.2009.0074
Novel nanoparticulate gel formulations of steroids for the treatment of macular edema.
S. H. S. Boddu (2010)
10.1021/JS950373B
Ocular penetration and bioconversion of prostaglandin F2alpha prodrugs in rabbit cornea and conjunctiva.
D. Chien (1997)
10.1016/J.IJPHARM.2003.11.032
Micellar solutions of triblock copolymer surfactants with pilocarpine.
I. Pepić (2004)
10.1021/MP0499499
Identification of a Na+-dependent cationic and neutral amino acid transporter, B(0,+), in human and rabbit cornea.
Blisse Jain-Vakkalagadda (2004)
Determination of tear volume and tear flow.
S. Mishima (1966)
10.1016/j.ijpharm.2011.01.004
Ocular biocompatibility of novel Cyclosporin A formulations based on methoxy poly(ethylene glycol)-hexylsubstituted poly(lactide) micelle carriers.
C. Di Tommaso (2011)
10.1007/s004170050159
A comparative investigation of FK506 and cyclosporin A in murine corneal transplantation
Alexander Reis (1998)
10.1167/IOVS.02-1112
Pharmacokinetic and toxicity study of an intraocular cyclosporine DDS in the anterior segment of rabbit eyes.
J. Theng (2003)
Some studies on the preservation of indometacin suspensions intended for ophthalmic use.
N. Vulovic (1990)
10.1007/978-1-4615-2417-5_53
Growth factors in human tear fluid and in lacrimal glands.
G. V. van Setten (1994)
10.1016/j.ijpharm.2008.08.004
Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: in vitro and in vivo results.
L. Gan (2009)
10.1097/00003226-200110000-00015
Prolongation of Corneal Allograft Survival Using Cyclosporine in a Polylactide-co-glycolide Polymer
L. Xie (2001)
10.1016/J.IJPHARM.2004.12.015
A novel water-soluble cyclosporine A prodrug: ocular tolerance and in vivo kinetics.
F. Lallemand (2005)
10.1089/JOP.1993.9.299
Effect of acylation on the ocular disposition of acyclovir. II: Corneal permeability and anti-HSV 1 activity of 2'-esters in rabbit epithelial keratitis.
P. Hughes (1993)
10.1016/j.ijpharm.2009.05.028
Polyhydroxyethylaspartamide-based micelles for ocular drug delivery.
C. Civiale (2009)
10.1089/JOP.2006.22.110
Modulation of P-glycoprotein-mediated efflux by prodrug derivatization: an approach involving peptide transporter-mediated influx across rabbit cornea.
Suresh Katragadda (2006)
10.1021/JS950474+
Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers.
P. Calvo (1996)
10.1080/02713680802518251
Molecular Expression and Functional Evidence of a Drug Efflux Pump (BCRP) in Human Corneal Epithelial Cells
P. Karla (2009)
10.1016/B978-0-12-374203-2.00080-4
Drug Delivery to Cornea and Conjunctiva: Esterase- and Protease-Directed Prodrug Design
Ravi S. Talluri (2010)
10.1081/DDC-100102312
Development of Model Aqueous Ophthalmic Solution of Indomethacin
E. Dimitrova (2000)
10.1016/S0161-6420(99)90262-2
Phase II results of an intraocular steroid delivery system for cataract surgery.
D. Chang (1999)
10.1016/S0928-0987(02)00057-X
Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen.
R. Pignatello (2002)
10.1021/JS9802594
Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye.
M. Prausnitz (1998)
[Formation and structure of lacrimal film on the ocular surface].
M. Prost (1989)
10.1089/JOP.1993.9.287
Effect of acylation on the ocular disposition of acyclovir. I: Synthesis, physicochemical properties, and antiviral activity of 2'-esters.
P. Hughes (1993)
10.1016/J.IJPHARM.2007.07.045
Preparation of rapamycin-loaded chitosan/PLA nanoparticles for immunosuppression in corneal transplantation.
Xubo Yuan (2008)
10.2220/BIOMEDRES.28.331
Eye-concentrated distribution of dexamethasone carried by sugar-chain modified liposome in experimental autoimmune uveoretinitis mice.
Y. Arakawa (2007)
10.1016/j.preteyeres.2012.05.003
Ocular surface inflammation is regulated by innate immunity
M. Ueta (2012)
10.1038/nrd2468
Prodrugs: design and clinical applications
J. Rautio (2008)
10.1016/S0168-3659(97)00212-5
Optimized release of dexamethasone and gentamicin from a soluble ocular insert for the treatment of external ophthalmic infections.
V. Baeyens (1998)
10.1023/A:1012123411343
Polar Solute Transport Across the Pigmented Rabbit Conjunctiva: Size Dependence and the Influence of 8-Bromo Cyclic Adenosine Monophosphate
Y. Horibe (2004)
10.1016/J.JCONREL.2007.05.009
Poly(N-isopropylacrylamide)-chitosan as thermosensitive in situ gel-forming system for ocular drug delivery.
Y. Cao (2007)
10.1089/JOP.1997.13.353
Pharmacological evaluation of anti-inflammatory pyrrole-acetic acid derivative eye drops.
C. Bucolo (1997)
10.1189/jlb.0108076
Inhibition of corneal inflammation by liposomal delivery of short‐chain, C‐6 ceramide
Y. Sun (2008)
10.1002/JPS.2600620712
Lacrimal and instilled fluid dynamics in rabbit eyes.
S. Chrai (1973)
10.1089/JOP.1995.11.509
Cyclosporine in collagen particles: corneal penetration and suppression of allograft rejection.
B. Gebhardt (1995)
10.1080/02713680500320752
FK506 in a Biodegradable Glycolide-co-Clatide-co-Caprolactone Polymer for Prolongation of Corneal Allograft Survival
W. Shi (2005)
10.1016/J.ADDR.2004.02.006
Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development.
S. Majumdar (2004)
10.1016/S0168-3659(96)01503-9
Ex-vivo permeation study of indomethacin from a submicron emulsion through albino rabbit cornea
S. Muchtar (1997)
10.1016/S0939-6411(03)00036-5
Influence of n-octenylsuccinate starch on in vitro permeation of sodium diclofenac across excised porcine cornea in comparison to Voltaren ophtha.
L. Baydoun (2003)
10.1517/17425247.3.4.511
Chemical modification and formulation approaches to elevated drug transport across cell membranes
S. Majumdar (2006)
10.1089/JOP.1986.2.67
Topical ocular drug delivery: recent developments and future challenges.
V. Lee (1986)
10.1089/JOP.2006.22.465
Corneal absorption and anterior chamber pharmacokinetics of dipeptide monoester prodrugs of ganciclovir (GCV): in vivo comparative evaluation of these prodrugs with Val-GCV and GCV in rabbits.
Sriram Gunda (2006)
10.1016/J.IJPHARM.2004.10.026
Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system.
Deepika Aggarwal (2005)
Presence of epidermal growth factor in human tears.
Y. Ohashi (1989)
10.1016/S0002-9394(14)70532-X
Causes of Uveitis in the General Practice of Ophthalmology
C. McCannel (1996)
10.1007/s00417-003-0753-2
Effects of a new dexamethasone-delivery system (Surodex) on experimental intraocular inflammation models
Masuhiro Kodama (2003)
10.1002/jgm.1093
Eye drop delivery of nano‐polymeric micelle formulated genes with cornea‐specific promoters
Yaw-Chong Tong (2007)
10.1007/BF00410700
Tear volume in normal eyes and keratoconjunctivitis sicca
D. Scherz (2004)
10.1080/02713680500306439
Identification and Characterization of a Na+-Dependent Neutral Amino Acid Transporter, ASCT1, in Rabbit Corneal Epithelial Cell Culture and Rabbit Cornea
Suresh Katragadda (2005)
10.1097/00003226-200203000-00015
Intraocular Dexamethasone Delivery System for Corneal Transplantation in an Animal Model
F. Kagaya (2002)
10.1081/DDC-120002997
Penetration Enhancers and Ocular Bioadhesives: Two New Avenues for Ophthalmic Drug Delivery
I. P. Kaur (2002)
10.1167/IOVS.02-1142
Molecular evidence and functional expression of P-glycoprotein (MDR1) in human and rabbit cornea and corneal epithelial cell lines.
S. Dey (2003)
10.1002/JPS.2600720310
Esterase activities in adult rabbit eyes.
V. H. Lee (1983)
10.1097/01.ico.0000178738.29459.59
New Drug Delivery for Corneal Neovascularization Using Polyion Complex Micelles
T. Usui (2005)
Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans.
J. Kristinsson (1996)
10.1016/j.ejpb.2011.05.006
Enhancing and sustaining the topical ocular delivery of fluconazole using chitosan solution and poloxamer/chitosan in situ forming gel.
T. Gratieri (2011)
Carrier-mediated transport of monocarboxylate drugs in the pigmented rabbit conjunctiva.
Y. Horibe (1998)
10.1023/A:1019806411610
Mechanism of Corneal Permeation of L-Valyl Ester of Acyclovir: Targeting the Oligopeptide Transporter on the Rabbit Cornea
Banmeet S. Anand (2004)
10.1089/JOP.2000.16.363
Pharmacokinetics and anti-inflammatory activity in rabbits of a novel indomethacin ophthalmic solution.
P. Chetoni (2000)
10.1016/0378-5173(92)90308-O
The effect of drug charge type and charge density on corneal transport
J. Liaw (1992)
10.1076/ceyr.21.5.843.5532
Immunolocalization of Na-K-ATPase, Na-K-Cl and Na-glucose cotransporters in the conjunctival epithelium
H. Turner (2000)
10.1016/j.ijpharm.2010.06.015
Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability.
L. Gan (2010)
10.1007/s12272-001-1266-6
Chitosan based nanocarriers for indomethacin ocular delivery
A. Badawi (2008)
10.1080/08830180212066
ANTERIOR CHAMBER ASSOCIATED IMMUNE DEVIATION (ACAID): REGULATION, BIOLOGICAL RELEVANCE, AND IMPLICATIONS FOR THERAPY
J. Stein-Streilein (2002)
10.1016/J.BBRC.2006.12.060
Accumulation of liposome with Sialyl Lewis X to inflammation and tumor region: application to in vivo bio-imaging.
M. Hirai (2007)
10.1076/ceyr.26.3.151.14893
Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea
Banmeet S. Anand (2003)
10.3109/02713689508995132
Active sodium and chloride transport across the isolated rabbit conjunctiva.
X. Shi (1995)
10.1016/J.IJPHARM.2006.11.031
Molecular evidence and functional expression of a novel drug efflux pump (ABCC2) in human corneal epithelium and rabbit cornea and its role in ocular drug efflux.
P. Karla (2007)
10.1016/S0939-6411(00)00108-9
Considerations in the use of hydroxypropyl-beta-cyclodextrin in the formulation of aqueous ophthalmic solutions of hydrocortisone.
A. Bary (2000)
10.1080/10717540701606426
Sustained Ocular Drug Delivery from a Temperature and pH Triggered Novel In Situ Gel System
H. Gupta (2007)
10.3109/10717544.2010.483255
New method for ophthalmic delivery of azithromycin by poloxamer/carbopol-based in situ gelling system
F. Cao (2010)
10.1097/ICO.0b013e31823f789e
Resolvin E1 (RX-10001) Reduces Corneal Epithelial Barrier Disruption and Protects Against Goblet Cell Loss in a Murine Model of Dry Eye
C. S. de Paiva (2012)
10.1089/JOP.2005.21.463
Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations.
S. Majumdar (2005)
10.1016/J.IJPHARM.2007.03.011
Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.
M. Kassem (2007)
10.1201/9780203912072-15
The Noncorneal Route in Ocular Drug Delivery
Imran Ahmed (2003)
10.1002/JPS.2600721110
Corneal penetration behavior of beta-blocking agents III: In vitro-in vivo correlations.
H. Huang (1983)
10.1016/j.ijpharm.2011.03.041
Novel NSAIDs ophthalmic formulation: flurbiprofen axetil emulsion with low irritancy and improved anti-inflammation effect.
J. Shen (2011)
10.1016/s0161-6420(82)34746-6
The corneal endothelium. Normal and pathologic structure and function.
G. Waring (1982)
10.1021/mp900279c
Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone bitherapy.
H. K. Ibrahim (2010)
10.1016/J.CARBPOL.2006.01.020
Preparation of cholesterol-modified chitosan self-aggregated nanoparticles for delivery of drugs to ocular surface
X. Yuan (2006)
10.1038/eye.1993.96
Comparison of tear film thickness in three species determined by the glass fibre method and confocal microscopy
J. Prydal (1993)
10.1208/s12249-008-9105-1
Niosome-Encapsulated Gentamicin for Ophthalmic Controlled Delivery
G. Abdelbary (2008)
10.1016/1350-9462(96)00014-6
Delivery of drugs to the eye by topical application
Hitoshi Sasaki (1996)
10.1016/J.CAP.2004.06.017
Biomedical nanotechnology for active drug delivery systems by applying sugar-chain molecular functions
N. Yamazaki (2005)
10.2174/157489112799829765
Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents.
A. D. Vadlapudi (2012)
10.1016/j.ijpharm.2008.03.015
Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections.
Suresh Katragadda (2008)
10.1016/j.exer.2011.02.015
Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.
G. Prasanna (2011)
10.2174/1877912311202010002
An Overview of Recent Patents on Nanocarrier Based Ophthalmic Drug Delivery Systems
Sulabh Patel (2012)
Study of precorneal tear film thickness and structure by interferometry and confocal microscopy.
J. Prydal (1992)
10.2165/00003088-199018040-00001
Ocular Drug Delivery
R. Schoenwald (1990)
10.3109/02713689509000007
Ocular aminopeptidase activity and distribution in the albino rabbit.
R. Stratford (1985)
10.1007/S10847-006-9253-4
Dexamethasone delivery to posterior segment of the eye
T. Loftsson (2007)
10.1016/j.ijpharm.2012.05.033
Targeted lipid based drug conjugates: a novel strategy for drug delivery.
A. D. Vadlapudi (2012)
10.1007/BF00137945
Epidermal growth factor in human tear fluid: A minireview
G. V. Setten (2004)
10.3109/02713688608996374
Effects of a new anti-allergic agent: the magnesium salt of N-acetyl-aspartyl-glutamic acid on experimental allergic inflammation of the rabbit eye.
P. Lapalus (1986)
10.1016/S0161-6420(01)00839-9
Randomized clinical trial of Surodex steroid drug delivery system for cataract surgery: anterior versus posterior placement of two Surodex in the eye.
D. Tan (2001)
10.1007/S10856-007-3307-Z
In vitro evaluation of poly(caporlactone) grafted dextran (PGD) nanoparticles with cancer cell
P. Prabu (2008)
10.1016/0304-3959(82)90092-6
Density and organization of free nerve endings in the corneal epithelium of the rabbit
A. J. Rózsa (1982)
10.2174/1877912311202020082
Novel Nanomicellar Formulation Approaches for Anterior and Posterior Segment Ocular Drug Delivery.
K. Cholkar (2012)
10.2174/1874104500802010066
Transcorneal Permeation in a Corneal Device of Non-Steroidal Anti-Inflammatory Drugs in Drug Delivery Systems
R. Valls (2008)
10.1023/A:1007508714259
Role of P-Glycoprotein in Restricting Propranolol Transport in Cultured Rabbit Conjunctival Epithelial Cell Layers
J. Yang (2004)
10.1097/00003226-200011002-00070
Metabolism and transport of purinergic receptor agonists in rabbit conjunctival epithelial cells.
H. Gukasyan (2000)
10.1089/108076803321637717
Intraocular availability of topically applied mycophenolate mofetil in rabbits.
S. Knapp (2003)
10.1517/14712598.2.6.607
Current prodrug strategies via membrane transporters/receptors
Banmeet S. Anand (2002)
Ocular Drug Delivery; Impact of in vitro Cell Culture Models
J. Barar (2009)
10.1016/S0142-9612(02)00080-7
Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application.
R. Pignatello (2002)
10.1002/jbm.b.31498
Toxicity evaluation of biodegradable and thermosensitive PEG-PCL-PEG hydrogel as a potential in situ sustained ophthalmic drug delivery system.
Hongbo Yin (2010)
10.1136/bjo.75.2.106
Recovery of the blood-aqueous barrier after cataract surgery.
V. Ferguson (1991)
10.1177/0885328211406563
Chitosan-based thermosensitive hydrogel as a promising ocular drug delivery system: Preparation, characterization, and in vivo evaluation
Xingwei Chen (2012)
10.1089/JOP.1996.12.481
Gamma scintigraphic comparison of eyedrops containing pilocarpine in healthy volunteers.
G. Meseguer (1996)
10.3109/03639041003801893
Preparation and evaluation of in situ gelling ophthalmic drug delivery system for methazolamide
Yong Qian (2010)
10.1081/DDC-120003445
Ocular Preparations: The Formulation Approach
Indu Pal Kaur (2002)
10.1006/CLIN.1996.0140
The mechanism of action of cyclosporin A and FK506.
S. Ho (1996)
10.1023/A:1015802427428
The Transport Barrier of Epithelia: A Comparative Study on Membrane Permeability and Charge Selectivity in the Rabbit
Y. Rojanasakul (2004)
10.1016/J.EXER.2006.08.015
Molecular evidence and functional expression of multidrug resistance associated protein (MRP) in rabbit corneal epithelial cells.
P. Karla (2007)
10.1016/J.EJPB.2005.01.009
Cell culture models of the ocular barriers.
M. Hornof (2005)
10.1167/iovs.07-1077
Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy.
M. de la Fuente (2008)
10.1002/jps.22422
Design and evaluation of controlled-release niosomes and discomes for naltrexone hydrochloride ocular delivery.
H. Abdelkader (2011)
Luteinizing hormone-releasing hormone agonist and transferrin functionalizations enhance nanoparticle delivery in a novel bovine ex vivo eye model.
U. Kompella (2006)
10.1016/J.EJPB.2007.03.011
Biological conversion of a water-soluble prodrug of cyclosporine A.
F. Lallemand (2007)
10.1081/DDC-52058
Characterization of the Novel Ophthalmic Drug Carrier Sophisen in Two of Its Derivatives: 3A Ofteno™ and Modusik-A Ofteno™
J. D. Quintana-Hau (2005)
10.1002/JPS.2600690418
Prelminary examination of rabbit conjunctival mucins.
V. Lee (1980)
10.1002/JPS.2600630304
Drop size and initial dosing frequency problems of topically applied ophthalmic drugs.
S. Chrai (1974)
10.1016/J.EJPB.2004.12.007
Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation.
K. Hosoya (2005)
10.2174/1389200043335342
Role of metabolism in ocular drug delivery.
Sridhar Duvvuri (2004)
10.1089/108076804772745482
Ocular permeability screening of dexamethasone esters through combined cellular and tissue systems.
C. Civiale (2004)
Pre-corneal tear film thickness in humans measured with a novel technique
Kaveh Azartash (2011)
10.1016/S0168-3659(99)00192-3
Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption.
S. Law (2000)
10.1023/A:1015845916293
Role of Enzymatic Lability in the Corneal and Conjunctival Penetration of Timolol Ester Prodrugs in the Pigmented Rabbit
Du-Shieng Chien (2004)
10.1016/S1350-9462(02)00038-1
Regulation of mucin and fluid secretion by conjunctival epithelial cells
D. Dartt (2002)
Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera.
K. M. Hämäläinen (1997)
10.1002/JPS.20685
Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration.
E. Vega (2006)



This paper is referenced by
10.4155/tde.15.73
Ophthalmic applications of lipid-based drug nanocarriers: an update of research and patenting activity.
R. Pignatello (2015)
10.3390/pharmaceutics12080767
Adeno-Associated Virus Mediated Gene Therapy for Corneal Diseases
Prabhakar Bastola (2020)
10.3390/pharmaceutics11090460
Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents
E. B. Souto (2019)
10.1208/s12249-014-0244-2
Nanomicellar Topical Aqueous Drop Formulation of Rapamycin for Back-of-the-Eye Delivery
K. Cholkar (2014)
10.1016/j.preteyeres.2016.12.001
Pharmacokinetic aspects of retinal drug delivery
E. Amo (2017)
10.22038/IJBMS.2016.6940
Design of eudragit RL nanoparticles by nanoemulsion method as carriers for ophthalmic drug delivery of ketotifen fumarate
Saieede Soltani (2016)
10.1002/adhm.201700733
Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation
Michelle L. Ratay (2017)
10.1111/jphp.12132
Topical delivery of ocular therapeutics: carrier systems and physical methods
J. G. Souza (2014)
Development and Preliminary In vitro Evaluation of Nanomicelles Laden In situ Gel of Dexamethasone for Ophthalmic Delivery
P. Chowdhury (2015)
10.3390/pharmaceutics12060570
Recent Advances in the Design of Topical Ophthalmic Delivery Systems in the Treatment of Ocular Surface Inflammation and Their Biopharmaceutical Evaluation
R. Mazet (2020)
10.1371/journal.pone.0191850
Intra-cameral level of ganciclovir gel, 0.15% following topical application for cytomegalovirus anterior segment infection: A pilot study
S. Waduthantri (2018)
10.1080/17425247.2016.1214565
Transporter effects on cell permeability in drug delivery
A. Mandal (2017)
Formulation Strategies to Address Physiological and Anatomical Constraints for Improved Topical Ocular Drug Delivery
Karthik Yadav Janga (2019)
10.1016/j.jconrel.2014.12.017
Tear-mediated delivery of nanoparticles through transcytosis of the lacrimal gland.
P. Hsueh (2015)
10.1021/acs.molpharmaceut.6b00445
Prolonged Ocular Retention of Mucoadhesive Nanoparticle Eye Drop Formulation Enables Treatment of Eye Diseases Using Significantly Reduced Dosage.
Shengyan Liu (2016)
10.2147/OPTH.S165722
Intracameral dexamethasone injection in the treatment of cataract surgery induced inflammation: design, development, and place in therapy
Tirth J. Shah (2018)
10.1007/978-3-319-47691-9_5
Topical Versus Systemic Ocular Drug Delivery
Lunawati L. Bennett (2016)
10.1016/j.jddst.2019.101389
Target strategies for drug delivery bypassing ocular barriers
R. Suri (2020)
10.1016/j.drudis.2019.03.018
The gap between the need for novel retinal drug delivery methods, technologies in R&D phase, and approved ocular drug delivery technologies.
Ron Neumann (2019)
10.1097/IJG.0000000000000109
Potential drug delivery approaches for XFS-associated and XFS-associated glaucoma.
Shreya S Kulkarni (2014)
10.1016/j.ijpharm.2020.119577
The prominence of the dosage form design to treat ocular diseases.
Patrícia Mazureki Campos (2020)
10.2174/1568026615666150108150217
Therapeutics and carriers: the dual role of proteins in nanoparticles for ocular delivery.
S. Pescina (2015)
Preparation of Pentablock Nanomicellar Formulations for Prostate Cancer Drug Delivery Systems
Alex Oselu Owiti (2018)
10.22159/AJPCR.2018.V11I5.24296
TOPICAL DRUG DELIVERY FOR EFFECTIVE TREATMENT OF BACTERIAL INFECTIONS OF THE ANTERIOR SEGMENT OF THE EYE
A. El-Bary (2018)
10.1016/J.COLCOM.2018.03.008
Recent Developments in Ophthalmic Drug Delivery Systems for Therapy of Both Anterior and Posterior Segment Diseases
H. Chen (2018)
10.1007/978-3-319-29346-2_9
Ocular Permeation Enhancers
N. Kim (2016)
10.11648/J.IJOVS.20170204.14
Recent Trends in Chitosan Based Nanotechnology: A Reference to Ocular Drug Delivery System
V. Gharge (2017)
10.1016/j.ejps.2019.03.007
Implantable drainage devices in glaucoma: Quo vadis?
K. S. Yadav (2019)
Development of Pentablock Copolymer Based Formulations for the Sustained Delivery of Protein Therapeutics in the Treatment of Posterior Segment Ocular Diseases
Sulabh P. Patel (2014)
10.15171/bi.2016.07
Advanced drug delivery and targeting technologies for the ocular diseases
J. Barar (2016)
10.3390/pharmaceutics10040208
Development and Evaluation of a Water Soluble Fluorometholone Eye Drop Formulation Employing Polymeric Micelle
Gyubin Noh (2018)
10.1007/978-3-030-41858-8_12
Effect of Drugs and Nanoformulation on Ocular Cells in Various Disease States
Sanjeev Kumar Paikra (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar